Certification Rate
100%
Very high DOL cert
A DOL Labor Condition Application record spanning FY2023–2026. Review the filing volume, DOL certification record, and offered-wage context below.
Newton, MA NAICS: 541714
U.S. Department of Labor's OFLC discloses 31 Labor Condition Application filings naming Karyopharm Therapeutics Inc. from FY2023 through FY2026, drawn directly from DOL's quarterly public disclosure releases. An LCA is the wage-and-working-conditions attestation an employer files with DOL before petitioning USCIS for an H-1B worker: it is a filing record, not a USCIS approval, a job offer, or a confirmed hire, and the count reflects filings, not people, since an employer sponsoring the same role at more than one worksite, or refiling across fiscal years, is counted once per filing. See filing history · Recent LCAs
Separate from the DOL filing record above, U.S. Citizenship and Immigration Services adjudicated 56 H-1B petitions naming Karyopharm Therapeutics Inc. through FY2024, and approved the large majority of them: 96.4% approved (54 approvals, 2 denials). A DOL certification is the labor-condition step filed before a petition; this USCIS figure is the actual adjudicated outcome, and the two rates commonly differ.
The verdict
Karyopharm Therapeutics Inc. is listed in 31 DOL LCA filings, more filings than 94% of employer filers in this extract. DOL certified 100% of those LCAs; the median listed offered wage is $140,300. This is not a USCIS approval, hiring, or sponsorship ranking.
According to U.S. Department of Labor OFLC LCA disclosure files (FY2023–FY2026). Based in Newton, MA.
Karyopharm Therapeutics Inc. vs all U.S. employer filers by LCA volume
Where this employer's disclosed Labor Condition Application count sits among every tracked employer filer (inventory signal, not a sponsorship ranking)
31 7990th of 122824 higher than 114,834 of 122,824 employer filers
Employer filers, banded by disclosed H-1B LCA filing count
Each bar is a band; taller bars hold more employer filers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source U.S. Department of Labor OFLC · FY2023–FY2026
Derived from this employer's disclosed LCAs on file (FY2023–FY2026), title mix and worksite counties, not national boilerplate. LCA filings do not establish USCIS outcomes or confirmed hiring.
Offered-wage span on file: $96,616–$190,215 .
DOL LCA release change
On 31 LCAs with comparable offered vs prevailing wages, Karyopharm Therapeutics Inc. averages about 13.9% above the prevailing wage (national baseline ≈ 17.8%). Dominant PW level on file: Fully Competent (Level IV) (41.9% of LCA filings).
Completed-year LCA counts fell from 16 in FY2023 to 8 in FY2025 (≈50% of the earlier year). Cumulative volume still 31.
Certification Rate
100%
Very high DOL cert
Avg. Salary
$140,300
Above portal avg
Total Workers
31
Small worker count
Compensation range for H-1B positions at Karyopharm Therapeutics Inc.
Wage vs. DOL Minimum
+13.9%
At/above DOL floor
national avg +17.8%
Typical DOL Wage Level
Fully Competent (Level IV)
41.9% of LCA filings
Full-Time Positions
100%
Primary Worksite County
NEWTON CITY, MA
48.4% of LCA filings
Most frequently listed job titles at Karyopharm Therapeutics Inc.
| Job Title | LCA filings | Avg. Salary |
|---|---|---|
| Sr Clinical Data Manager | 4 | $123,179 |
| Senior Manager, Regulatory Operations | 4 | $177,350 |
| Sr Scientist, Analytical Chemistry | 3 | $150,241 |
| Senior Clinical Data Manager | 3 | $125,719 |
| Sr. Clinical Trial Manager | 2 | $160,000 |
| Pharmacovigilance Specialist | 2 | $110,000 |
| Manager, Regulatory Operations | 2 | $134,966 |
| Manager, Regulatory Affairs | 2 | $120,000 |
| Associate Director, IST Operations | 2 | $124,747 |
| Sr Scientist Bioanalytical | 1 | $145,000 |
| Senior Statistical Programmer 1 | 1 | $123,966 |
| SENIOR BIOSTATISTICIAN | 1 | $187,044 |
| Manager Regulatory Operations | 1 | $109,745 |
| GCP Documentation Specialist | 1 | $96,616 |
| Associate Director, XPOVIO U.S. Multiple Myeloma Marketing | 1 | $169,000 |
Cross-state DOL neighbors for Karyopharm Therapeutics Inc. - LCA filing-count and offered-wage axes, outside MA.
Nearest cross-state employer filers by LCA filing count (31 here; floor ≥10 LCA filings).
Cross-state employer filers with a comparable average listed offered wage ($140,300 here).
Karyopharm Therapeutics Inc. is listed in 31 DOL Labor Condition Application filings covering 31 listed worker positions from FY2023 to FY2026. An LCA is a Labor Department filing record, not confirmation of a USCIS petition, hire, sponsorship, or visa approval.
Among 122,824 employer filers in the DOL disclosure extract, Karyopharm Therapeutics Inc. ranks #7786 by total LCA filing count (31 filings). 114,834 employer filers have fewer disclosed filings in this extract. This is a filing-volume comparison only, not a USCIS approval, hiring, or sponsorship ranking.
Karyopharm Therapeutics Inc. has a 100% DOL certification rate, with 31 out of 31 LCA filings certified. That is the Labor Department step, not a USCIS visa approval rate.
The average offered wage listed in Karyopharm Therapeutics Inc.'s LCAs is $140,300. Listed wages range from $96,616 to $190,215 and are not verified actual compensation.
The top job titles in Karyopharm Therapeutics Inc.'s LCA filing records include Sr Clinical Data Manager, Senior Manager, Regulatory Operations, Sr Scientist, Analytical Chemistry. The most common listed title is Sr Clinical Data Manager with 4 LCA filings at an average listed offered wage of $123,179. This does not establish actual job openings, hiring, or approved petitions.
Karyopharm Therapeutics Inc. is headquartered in Newton, MA. Their H-1B workers are distributed across 6 states, with the most positions in MA, VA, AR.
No, Karyopharm Therapeutics Inc. is not classified as H-1B dependent.
Karyopharm Therapeutics Inc. is listed in 16 LCA filings in FY2023 and 5 in FY2026. The average listed offered wage increased from $133,309 to $174,835. This historical filing series does not predict sponsorship, hiring, or visa outcomes.
Disclaimer: Informational only, not professional advice.
ABS(total_petitions) peers first, then a LARGEST-distance pole and a stamp-branched drill, not a fixed Related strip. This page stamps MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 31 LCAs (Δ 0 heavier vs Karyopharm Therapeutics Inc.); CERT-LOCK · WAGE-BELOW vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 31 LCAs (Δ 0 heavier vs Karyopharm Therapeutics Inc.); CERT-SOLID · WAGE-ELITE vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 31 LCAs (Δ 0 heavier vs Karyopharm Therapeutics Inc.); CERT-LOCK · WAGE-BELOW vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 31 LCAs (Δ 0 heavier vs Karyopharm Therapeutics Inc.); CERT-LOCK · WAGE-ELITE vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
MA pole at 3,809 LCAs stamps HEAVY-BOOK · CERT-CLEAN, farthest ABS(total_petitions) contrast from Karyopharm Therapeutics Inc.'s MICRO-BOOK.
Open the MA state board after the ABS peers. Karyopharm Therapeutics Inc. stamps MICRO-BOOK · CERT-LOCK inside that worksite mix.
Karyopharm Therapeutics Inc.'s WAGE-PREMIUM offered-wage posture needs occupation/state context, not a shared guide card.
What to do with this profile
Use the DOL LCA record for Karyopharm Therapeutics Inc. to compare filing volume and offered wages, not USCIS outcomes.
DOL disclosure data only. Not legal advice, sponsorship guarantees, or visa eligibility.
Every figure on PlainVisa is rendered directly from federal source data, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error. Data current as of 2026-09-09.